最近在直接心脏重编程方面的进展和未来前景.
Yifang Xie1,2, Ben Van Handel3, Li Qian1,2
1McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nature cardiovascular research
|August 28, 2024
概括
直接的心脏重编程将纤维细胞转化为心肌细胞类细胞 (iCMs),以修复心脏损伤. 本综述涵盖了临床使用的重编程方法,机制和挑战.
科学领域:
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
- 分子生物学分子生物学
背景情况:
- 心血管疾病是全球主要的健康问题.
- 心肌梗塞后心肌细胞的有限再生导致心力衰竭.
- 直接心脏重编程提供了一种潜在的治疗策略,以取代丢失的心肌细胞.
研究的目的:
- 审查用于产生诱导心肌细胞样细胞 (iCMs) 的心脏重编程尾酒.
- 探索关于心脏重编程障碍和促进者的机制研究.
- 讨论最近的进展,包括单细胞"奥米克"研究,以及临床翻译的障碍.
主要方法:
- 关于心脏重编程尾酒 (转录因子,微RNA,小分子) 的文献综述.
- 对研究重编程过程的机械学研究的分析.
- 对单细胞"omics"数据的检查,以深入了解iCM生成.
主要成果:
- 各种重编程尾酒有效地从心脏纤维细胞产生iCM.
- 机理学研究揭示了影响重编程效率的关键因素.
- 单细胞"omics"技术提供了高分辨率的洞察力,可以在重新编程过程中了解细胞的转换.
结论:
- 直接心脏重编程是治疗心力衰竭的一个有希望的策略.
- 了解重编程机制和障碍对于优化iCM生成至关重要.
- 克服障碍对于心脏重编程疗法的临床应用至关重要.
相关概念视频
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Overview of the Heart
32.2K
The heart, a muscular organ located in the chest, functions as the body's pump, circulating blood through the vascular system. It has four chambers: two atria on top and two ventricles below. The right atrium receives deoxygenated blood from the body and passes it to the right ventricle, which pumps it to the lungs for oxygenation. The left atrium receives oxygenated blood from the lungs and transfers it to the left ventricle, which pumps it to the rest of the body.
The heart's structure...
The heart's structure...
32.2K
Development of the Heart
3.9K
The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
3.9K
Heart Failure I: Introduction
1.7K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.7K
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626


